Biodexa Pharmaceuticals (BDRX) Operating Income (2013 - 2025)

Biodexa Pharmaceuticals (BDRX) has 12 years of Operating Income data on file, last reported at -$5.4 million in Q2 2025.

• For the quarter ending Q2 2025, Operating Income changed N/A year-over-year to -$5.4 million; the trailing twelve-month figure through Jun 2025 stood at -$20.5 million (changed N/A YoY), and the FY2025 full-year result was -$11.4 million, up 3.46% from the prior year.
• Operating Income rose to -$5.4 million in Q2 2025, from -$5.4 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of -$4.4 million in Q4 2021 to a low of -$5.4 million in Q4 2024.
• A 5-year average of -$4.9 million and a median of -$4.7 million in 2022 frame the typical range for Operating Income.
• Across the five-year window, Operating Income soared 85.67% in 2021 and slipped 3.98% in 2022, its largest moves.
• Tracing BDRX's Operating Income over 5 years: stood at -$4.4 million in 2021, then decreased by 1.65% to -$4.4 million in 2022, then decreased by 19.85% to -$5.3 million in 2023, then declined by 2.06% to -$5.4 million in 2024, then gained by 1.16% to -$5.4 million in 2025.
• Business Quant data shows BDRX's Operating Income at -$5.4 million in Q2 2025, -$5.4 million in Q4 2024, and -$5.3 million in Q2 2023.